falsefalse

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas - Episode 2

Currently Available Treatment Options for Patients With R/R DLBCL

,

Drs Loretta J. Nastoupil and Marc S Hoffman explain the available treatment options for relapsed/refractory diffuse large B-cell lymphoma and what to consider when selecting a therapy in the second-line setting.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Now Viewing
    EP. 2: Currently Available Treatment Options for Patients With R/R DLBCL
    EP. 3: ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
    EP. 4: Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
    EP. 5: Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
    EP. 6: Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)
    EP. 7: CAR T-Cell Therapy for Patients With R/R FL
    EP. 8: Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

    Related Content:

    Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in LymphomasNon-Hodgkin LymphomaCAR T-cell TherapyConferenceOncLive News Network®
    The OncFive: Top Oncology Articles for the Week of 4/27
    sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL
    Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial
    x